$CHYM

FRANKEL ADAM B sold $52K of CHYM

FRANKEL ADAM B (General Counsel) sold 3,000 shares of Chime Financial, Inc. (CHYM) at $17.50 on 2026-06-15.

Original reporting
SEC EDGAR · FRANKEL ADAM B
Published Jun 16, 2026, 9:39 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 16, 2026, 9:40 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CHYM
Neutral
medium confidence
Mentioned
$CHYM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CHYMNeutralLow
01

Why it matters

The newest fact is the disclosed open-market sale by the company’s General Counsel: 3,000 shares at $17.50 on 2026-06-15, with holdings after the sale of 303,795 shares.

02

Market read

Traders may treat the filing as a modest sentiment input, but it is not a fundamental catalyst by itself.

03

What to watch

No 10b5-1 plan is stated, which may prompt traders to scrutinize whether the sale was discretionary; also, the filing does not reveal whether other insiders simultaneously bought/sold, which could change interpretation.

Relevance 3/10Novelty 8/10Timing: SEC Form 4 filed 2026-06-16 (sale dated 2026-06-15)

Background

This is a primary-source SEC Form 4 insider transaction disclosure for Chime Financial, Inc.

Company-level read

Ticker impact

$CHYMNeutralMedium confidence
Context

Chime Financial’s General Counsel (Adam B. Frankel) sold 3,000 CHYM shares in an open-market transaction on 2026-06-15.

Expected impact

Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by broader insider activity or new fundamentals.

Evidence & confidence

The filing is a disclosed insider sale (not a buy), but it is not tied to a new business event; also no 10b5-1 plan is indicated, which can increase attention but still typically remains a sentiment-only datapoint.

Market effects

Minimal; insider sale does not indicate sector-wide change for fintech/consumer finance.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or pre-planned liquidity needs rather than bearish expectations, especially when the transaction size is not described as extraordinary.

Key entities

  • Chime Financial, Inc.

    Subject of the Form 4 insider transaction; General Counsel sold shares.

  • Adam B. Frankel

    General Counsel who executed the open-market sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CHYMHigh

Why is Chime Financial stock gaining today?

Chime Financial (CHYM) stock rose 1.5% in pre-market trading after Deutsche Bank upgraded it to Buy and raised its price target to $35. The bank cited strong Q2 2026 results, including 27% revenue growth and GAAP profitability, as well as growth in MyPay and Chime Prime. The upgrade also boosted FY27 adjusted EBITDA estimates by $71 million.

$CHYMMed

Deutsche Bank Upgrades Chime (CHYM) to Buy, Raises Price Target

Deutsche Bank upgraded Chime Financial Inc (CHYM) to Buy, raising its price target to $35. The bank cited strong product momentum and market expansion potential, particularly with MyPay and Chime Prime. Chime's P/S ratio is 4.85, above its historical and industry medians, reflecting growth expectations. Insider activity shows significant net selling, while institutional ownership trends are mixed.

$CHYMMed

Chime Financial Slides as Recent Insider Sales Likely Weigh on Shares

Chime Financial (CHYM) shares fell 7.5% today, likely due to recent insider and major-holder sales, including 3.2 million shares sold by DST Global and 447,637 shares by director James Feuille. The decline follows Chime's announcement of a $590 million bank acquisition, with no new negative updates reported. Analysts' median price target for CHYM is $28.0.